Browsing: PICO

Semaglutide

STEP-HFpEF Pooled Analysis

By FWADecember 27, 20240

Summary: In adults aged 18 years or older with obesity-related heart failure with preserved ejection fraction (HFpEF), characterized by a…

Semaglutide

Semaglutide and Obesity-Related Heart Failure

By FWADecember 27, 20240

Summary: In patients with heart failure with preserved ejection fraction, obesity (BMI ≥30), and type 2 diabetes, once-weekly semaglutide (2.4…

PICO

Tirzepatide Phase 1 Trial

By FWADecember 27, 20240

Summary: In adults with long-standing type 2 diabetes inadequately controlled, subcutaneous tirzepatide, a dual agonist of GIP and GLP-1 receptors…

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

CONTACT INFO

Privacy Policy
Disclaimer

Browsing: PICO

STEP-HFpEF Pooled Analysis

Semaglutide and Obesity-Related Heart Failure

Tirzepatide Phase 1 Trial

Once-Weekly Semaglutide Shows Promise in Improving Glycaemic Control and Weight Loss for Type 2 Diabetes Patients, Study Finds

Study Finds Semaglutide Reduces Cardiovascular Risk in Type 2 Diabetes Patients, but Raises Retinopathy Concerns

Study Shows Once-Weekly Semaglutide Effectively Lowers Blood Sugar and Aids Weight Loss in Type 2 Diabetes Patients

Once-Weekly Semaglutide Outperforms Daily Sitagliptin in Blood Sugar and Weight Control for Type 2 Diabetes Patients

Subscribe now

CATEGORIES

CONTACT INFO